secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001104659-24-035544
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics reports FY2023 net loss of $10.5M; AJ201 Phase 1b/2a enrollment complete, topline data Q2 2024
--------------------------------------------------------------------------------

- Net loss of $10.5M ($0.98 per share) vs $3.6M loss in FY2022; cash $1.8M as of Dec 31, 2023.
- Completed enrollment in AJ201 Phase 1b/2a for SBMA (25 patients); topline data expected Q2 2024.
- Reached final agreement with FDA on Phase 3 safety study protocol for IV tramadol; aims to initiate pending financing.
- Nasdaq granted extension to May 20, 2024 to meet continued listing requirements.
- Raised $5.0M gross in January 2024 via warrant inducement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465924035544/0001104659-24-035544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465924035544/tm248747d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-035544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer